Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

June 13, 2019 by Alan Khadavi

Dupixent for Hives

Dupixent for hives is novel treatment option for patients with difficult to treatment chronic spontaneous urticaria.  Chronic hives is a common condition marked by episodes of elevated, itching, red wheals persisting for more than 6 weeks without a specific known cause.  It is estimated that chronic hives affects about 1% of the population.

The mechanism of action of chronic hives is not well understood, however it is rooted in mast cell activation and degranulation.  Many treatments exist for chronic spontaneous urticaria, although they may not be effective in all cases.

Stepwise approach to Chronic Urticaria (Chronic Hives)

Xolair is a monoclonal antibody that is effective but not in all cases.

FDA approves Xolair for Chronic Urticaria

Some studies reported it is not effective in up to 1/3 of cases.  Cyclosporine is also effective, but many patients are hesitant to use it because of reported side effects and monitoring.

Severe Hives Treatment (Xolair and Cyclosporine)

A recent study published in the Journal of Allergy and Clinical Immunology, titled “Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria” looked at to see if Dupixent was a reasonable therapy for Omalizumab (Xolair) treatment failures.

Currently dupilumab is approved for moderate to severe atopic dermatitis and moderate to severe asthma.

Dupilumab (Dupixent) for Atopic Dermatitis (Eczema) Sufferers

Dupilumab for Asthma, a New Indication

And other indications may be coming. Dupilumab for Nasal Polyps

In the study published, 6 patients who failed Xolair for chronic hives were treated with Dupixent of up to 600mg monthly, who responded to it.  This may point to a mechanism of involving IL-4 and IL-13.  Thy may occur from IL-4 blocking the induction of B cell to plasma cell subclass switching from IgM to IgE as well as limiting the IL-13 inflammatory cascade that leads to itching in eczema and hives.

This report strongly suggests that Dupixent for hives has a potential role in chronic idiopathic urticaria and it warrants further studies.

Filed Under: biologics, Blog, hives, Urticaria

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

January 16, 2021

Singulair psychiatric side effects; a large study

Singulair psychiatric side effects

January 11, 2021

Allegra during Pregnancy, is it safe?

allegra during pregnancy

December 25, 2020

Moderna Covid Vaccine and Allergy

moderna covid vaccine and allergy

December 12, 2020

Pfizer Covid Vaccine and Allergy

covid vaccine and allergy

December 3, 2020

Budesonide Oral Suspension for Eosinophilic Esophagitis

budesonide oral suspension

December 1, 2020

Indacaterol for severe asthma

indacaterol

November 3, 2020

New treatments for chronic hives

New treatments for chronic hives

October 29, 2020

Xolair for Allergic Rhinitis-A recent study

xolair for allergic rhinitis

October 26, 2020

Semen allergy an overview and treatment

semen allergy

October 21, 2020

Peanut Patch (Viaskin) for peanut allergy

viaskin peanut patch

Read More Posts...

Follow Us…

© 2021 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page